Aug. 6 at 12:41 AM
$TVTX Lots of upgrades:
On August 5, 2026, Citigroup analyst Yigal Nochomovitz maintained a Buy rating on Travere Therapeutics (NASDAQ: TVTX) and raised the stock's price target to
$85.00 from
$70.00.
On August 5, 2026, Guggenheim analyst Vamil Divan maintained a 'Buy' rating on Travere Therapeutics Inc (TVTX) while raising the price target from
$65.00 to
$75.00.
BoA raises from
$64 to
$71. Projects peak revenues of
$2.1B for 2032.
Travere Therapeutics Inc TVTX received an analyst rating update from Evercore ISI Group, which maintained an "Outperform" rating and raised the price target from
$60.00 to
$68.00, reflecting a 13.33% increase.
